Ligand Pharmaceuticals (LGND) Short Interest Ratio & Short Volume $153.26 +2.18 (+1.44%) Closing price 04:00 PM EasternExtended Trading$153.32 +0.06 (+0.04%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ligand Pharmaceuticals Short Interest DataLigand Pharmaceuticals (LGND) has a short interest of 915,900 shares, representing 5.10% of the float (the number of shares available for trading by the public). This marks a -25.54% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.4, indicating that it would take 5.4 days of the average trading volume of 148,427 shares to cover all short positions.Current Short Interest915,900 sharesPrevious Short Interest1,230,000 sharesChange Vs. Previous Month-25.54%Dollar Volume Sold Short$120.51 millionShort Interest Ratio5.4 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares19,597,000 sharesShort Percent of Float5.10%Today's Trading Volume203,953 sharesAverage Trading Volume148,427 sharesToday's Volume Vs. Average137% Short Selling Ligand Pharmaceuticals? Sign up to receive the latest short interest report for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLGND Short Interest Over TimeLGND Days to Cover Over TimeLGND Percentage of Float Shorted Over Time Ligand Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025915,900 shares $120.51 million -25.5%5.1%5.4 $131.58 7/15/20251,230,000 shares $152.89 million +3.4%N/A8.7 $124.30 6/30/20251,190,000 shares $135.28 million +3.5%6.6%9.7 $113.68 6/15/20251,150,000 shares $129.38 million -6.5%6.4%9.7 $112.50 5/31/20251,230,000 shares $126.90 million +12.8%6.9%10.2 $103.17 5/15/20251,090,000 shares $112.78 million -10.7%6.1%8.9 $103.47 4/30/20251,220,000 shares $134.03 million +7.0%N/A10.2 $109.86 4/15/20251,140,000 shares $121.75 million +12.9%6.4%10.1 $106.80 3/31/20251,010,000 shares $106.19 million +5.8%5.7%9 $105.14 3/15/2025955,100 shares $101.42 million +22.4%5.4%8.3 $106.19 Get the Latest News and Ratings for LGND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/2025780,100 shares $95.35 million -7.7%4.4%7.1 $122.23 2/15/2025845,000 shares $101.40 million -11.2%4.8%8 $120.00 1/31/2025951,500 shares $110.90 million +4.4%N/A8.2 $116.55 1/15/2025911,400 shares $100.51 million +1.3%N/A7.4 $110.28 12/31/2024900,100 shares $96.45 million +10.7%N/A7.5 $107.15 12/15/2024812,800 shares $95.02 million +3.5%N/A6.9 $116.91 11/30/2024785,700 shares $95.44 million -5.5%N/A7.1 $121.47 11/15/2024831,500 shares $92.89 million -9.5%N/A7.5 $111.71 10/31/2024918,600 shares $97.10 million -8.1%N/A8.5 $105.70 10/15/20241,000,000 shares $104.39 million +0.4%N/A9.5 $104.39 9/30/2024996,100 shares $99.70 million +1.9%N/A8.7 $100.09 9/15/2024977,400 shares $102.40 million -1.8%N/A7.9 $104.77 8/31/2024995,000 shares $105.27 million -6.1%N/A8.1 $105.80 8/15/20241,060,000 shares $109.32 million +10.3%N/A8.3 $103.13 7/31/2024960,700 shares $104.71 million -12.7%N/A6.9 $108.99 7/15/20241,100,000 shares $106.34 million +17.7%N/A7.9 $96.67 6/30/2024934,400 shares $78.73 million -0.2%N/A6.5 $84.26 6/15/2024936,600 shares $74.98 million +32.3%N/A6.6 $80.06 5/31/2024707,700 shares $60.19 million -17.6%N/A4.3 $85.05 5/15/2024858,700 shares $73.65 million +7.9%N/A4.6 $85.77 4/30/2024795,600 shares $55.60 million -3.8%N/A4.3 $69.89 4/15/2024826,600 shares $65.94 million +23.0%5.0%4.9 $79.77 3/31/2024672,100 shares $49.13 million -23.3%4.1%4.1 $73.10 3/15/2024876,300 shares $62.30 million +14.9%5.3%5.8 $71.09 2/29/2024762,600 shares $60.51 million -15.0%4.6%5.3 $79.35 2/15/2024896,600 shares $66.93 million -3.6%5.5%7.3 $74.65 1/31/2024929,800 shares $67.97 million +1.0%5.7%8.1 $73.10 1/15/2024920,700 shares $66.84 million +2.2%6.9%8.2 $72.60 12/31/2023900,800 shares $64.34 million +0.8%5.5%8.2 $71.42 12/15/2023893,600 shares $60.18 million -1.7%5.5%8.1 $67.35Is Elon's empire crumbling? (Ad)The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. Click here to see the Tesla shock that could blindside everyone. 11/30/2023909,100 shares $53.01 million -2.3%5.5%8.8 $58.31 11/15/2023930,200 shares $52.54 million +6.1%5.7%9.2 $56.48 10/31/2023876,400 shares $45.83 million +3.8%5.4%8.8 $52.29 10/15/2023844,700 shares $46.45 million +2.5%5.2%8.8 $54.99 9/30/2023824,100 shares $49.38 million -0.1%5.1%8.4 $59.92 9/15/2023825,000 shares $51.13 million -6.2%5.1%8.8 $61.98 8/31/2023879,200 shares $57.82 million +4.6%5.4%9.1 $65.77 8/15/2023840,500 shares $56.81 million +4.3%5.2%8.6 $67.59 7/31/2023805,800 shares $53.93 million -3.4%5.0%8.2 $66.93 7/15/2023834,300 shares $56.61 million -1.4%5.1%8.4 $67.85 6/30/2023846,200 shares $61.01 million +4.0%5.2%8.6 $72.10 6/15/2023814,000 shares $64.30 million -1.6%5.0%7.8 $78.99 5/31/2023827,100 shares $57.96 million +1.3%5.1%7.9 $70.08 5/15/2023816,400 shares $63.34 million +0.7%5.0%7.2 $77.59 4/30/2023811,100 shares $61.93 million +5.1%5.1%7 $76.35 4/15/2023771,800 shares $57.38 million -1.0%4.8%6.6 $74.34 3/31/2023779,200 shares $57.32 million -13.5%4.9%6.5 $73.56 3/15/2023900,500 shares $64.48 million +7.5%5.6%7.1 $71.61 2/28/2023838,100 shares $60.46 million +2.5%5.2%5.1 $72.14 2/15/2023817,900 shares $59.69 million +1.5%5.1%4.8 $72.98 1/31/2023806,000 shares $56.18 million +0.1%5.1%4.6 $69.70 1/15/2023805,000 shares $57.38 million +1.5%5.1%4.1 $71.28 12/30/2022792,800 shares $52.96 million -8.4%5.0%4.1 $66.80 12/15/2022865,800 shares $53.81 million +13.0%5.5%4.4 $62.15 11/30/2022766,100 shares $55.85 million -2.3%4.8%4.6 $72.90 11/15/2022784,100 shares $61.99 million +6.6%4.9%5 $79.06 10/31/2022735,400 shares $64.46 million -0.3%4.6%5 $87.65 10/15/2022737,800 shares $66.03 million -6.7%4.6%6 $89.49 9/30/2022790,600 shares $68.08 million -5.1%5.0%6.6 $86.11 9/15/2022833,000 shares $75.08 million +3.1%5.2%7 $90.13 8/31/2022808,200 shares $74.67 million -3.7%5.1%6.6 $92.39 8/15/2022839,000 shares $90.03 million -3.2%5.3%6.8 $107.31 7/31/2022866,700 shares $79.76 million -0.8%5.4%6.5 $92.03 7/15/2022873,600 shares $82.58 million -3.6%5.4%6 $94.53 6/30/2022905,800 shares $80.82 million -0.2%5.6%6 $89.22 6/15/2022907,900 shares $71.80 million -0.6%N/A5.7 $79.08 5/31/2022913,400 shares $81.21 million -10.5%5.7%6.2 $88.91 5/15/20221,020,000 shares $87.68 million -8.9%6.4%6.2 $85.96 4/30/20221,120,000 shares $104.00 million No Change7.0%6.8 $92.86 4/15/20221,120,000 shares $117.89 million -8.9%7.0%6.8 $105.26 3/31/20221,230,000 shares $138.36 million +2.5%7.7%7.2 $112.49 3/15/20221,200,000 shares $125.44 million -2.4%7.5%7.5 $104.53 2/28/20221,230,000 shares $124.50 million No Change7.7%7.7 $101.22 2/15/20221,230,000 shares $152.13 million -10.2%7.8%8.1 $123.68 1/31/20221,370,000 shares $170.74 million -11.0%8.6%9.7 $124.63 1/15/20221,540,000 shares $192.36 million -4.4%9.7%11.3 $124.91 12/31/20211,610,000 shares $248.68 million -4.2%10.1%13.4 $154.46 12/15/20211,680,000 shares $247.80 million +5.0%10.6%13.9 $147.50 11/30/20211,600,000 shares $259.07 million +0.6%10.1%13.5 $161.92 11/15/20211,590,000 shares $260.93 million -4.2%10.0%8 $164.11Is Elon's empire crumbling? (Ad)The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. Click here to see the Tesla shock that could blindside everyone. 10/29/20211,660,000 shares $242.26 million No Change10.5%8 $145.94 10/15/20211,660,000 shares $216.23 million -4.1%10.5%7.9 $130.26 9/30/20211,730,000 shares $241.02 million -2.8%10.9%8 $139.32 9/15/20211,780,000 shares $241.83 million +10.6%11.2%7.8 $135.86 8/31/20211,610,000 shares $213.00 million -0.6%10.2%7 $132.30 8/13/20211,620,000 shares $173.05 million -1.8%10.2%10.1 $106.82 7/30/20211,650,000 shares $187.29 million -6.3%10.4%11 $113.51 7/15/20211,760,000 shares $203.84 million +0.6%11.1%11.7 $115.82 6/30/20211,750,000 shares $229.58 million +1.7%11.0%11.7 $131.19 6/15/20211,720,000 shares $212.97 million +8.2%10.8%12 $123.82 5/28/20211,590,000 shares $187.14 million -0.6%10.0%9.8 $117.70 5/14/20211,600,000 shares $198.21 million -0.6%10.1%8.5 $123.88 4/30/20211,610,000 shares $234.69 million +2.6%10.1%6.1 $145.77 4/15/20211,570,000 shares $237.12 million +4.7%9.9%2.9 $151.03 3/31/20211,500,000 shares $223.67 million -19.4%9.5%2.6 $149.11 3/15/20211,860,000 shares $306.49 million -15.8%11.8%3 $164.78 2/26/20212,210,000 shares $331.96 million -19.3%14.0%3.6 $150.21 2/12/20212,740,000 shares $493.31 million -54.1%17.9%4.5 $180.04 1/29/20215,970,000 shares $1.14 billion -40.4%38.9%10.3 $191.59 1/15/202110,010,000 shares $1.22 billion +1.0%64.9%21.5 $122.28 12/31/20209,910,000 shares $1.02 billion -0.7%64.2%28.9 $102.63 12/15/20209,980,000 shares $1.02 billion -1.6%64.7%29.5 $101.79 11/30/202010,140,000 shares $871.23 million -4.6%65.7%30.6 $85.92 11/15/202010,630,000 shares $889.84 million -1.0%68.9%32.7 $83.71 10/30/202010,740,000 shares $892.17 million +5.1%69.6%34.8 $83.07 10/15/202010,220,000 shares $1.02 billion +3.9%66.2%34.7 $100.01 9/30/20209,840,000 shares $937.95 million +6.0%63.8%39.7 $95.32 9/15/20209,280,000 shares $890.79 million +3.0%60.1%35 $95.99 8/31/20209,010,000 shares $919.02 million +0.9%58.4%34.6 $102.00 LGND Short Interest - Frequently Asked Questions What is Ligand Pharmaceuticals' current short interest? Short interest is the volume of Ligand Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 915,900 shares of LGND short. 5.10% of Ligand Pharmaceuticals' shares are currently sold short. Learn More on Ligand Pharmaceuticals' current short interest. What is a good short interest ratio for Ligand Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LGND shares currently have a short interest ratio of 5.0. Learn More on Ligand Pharmaceuticals's short interest ratio. Which institutional investors are shorting Ligand Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ligand Pharmaceuticals: Group One Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Ligand Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.10% of Ligand Pharmaceuticals' floating shares are currently sold short. Is Ligand Pharmaceuticals' short interest increasing or decreasing? Ligand Pharmaceuticals saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 915,900 shares, a decrease of 25.5% from the previous total of 1,230,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Ligand Pharmaceuticals' short interest compare to its competitors? 5.10% of Ligand Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Ligand Pharmaceuticals: ADMA Biologics Inc (5.96%), ANI Pharmaceuticals, Inc. (11.48%), BioMarin Pharmaceutical Inc. (2.71%), Exelixis, Inc. (6.67%), Exact Sciences Corporation (3.68%), Halozyme Therapeutics, Inc. (8.58%), Madrigal Pharmaceuticals, Inc. (22.84%), Ionis Pharmaceuticals, Inc. (7.45%), Repligen Corporation (6.84%), Alkermes plc (8.76%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Ligand Pharmaceuticals stock? Short selling LGND is an investing strategy that aims to generate trading profit from Ligand Pharmaceuticals as its price is falling. LGND shares are trading down $2.71 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ligand Pharmaceuticals? A short squeeze for Ligand Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LGND, which in turn drives the price of the stock up even further. How often is Ligand Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LGND, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies ADMA Biologics Short Interest Data ANI Pharmaceuticals Short Interest Data BioMarin Pharmaceutical Short Interest Data Exelixis Short Interest Data Exact Sciences Short Interest Data Halozyme Therapeutics Short Interest Data Madrigal Pharmaceuticals Short Interest Data Ionis Pharmaceuticals Short Interest Data Repligen Short Interest Data Alkermes Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LGND) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access